医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Notice of Establishment: New Company, Denka-KEW Genomics

2017年03月18日 AM02:34
このエントリーをはてなブックマークに追加


 

CAMBRIDGE, Mass.

Today, we announce that on February 15, 2017, KEW, Inc., a privately-held molecular diagnostics company located in Cambridge, MA, USA and Denka, Co., Ltd. , a commercial manufacturing company of chemical and life science products, located in Tokyo, Japan, officially entered into a joint venture, Denka-KEW Genomics LLC (“DKGX”), for the purposes of providing comprehensive genomic profiling to cancer patients in Japan and guiding therapeutic decisions based on individual patient tumor profiles.

“In October, 2015, KEW and Denka announced a strategic collaboration to establish the feasibility of using CANCERPLEX in Japanese patients. Our recent publication in Genome Medicine (2016) is the culmination of these efforts and serves as the basis for our establishing DKGX,” said Raju Kucherlapati, Ph.D., Paul C. Cabot Professor of Genetics and Professor of Medicine at Harvard Medical School and co-founder of KEW, Inc.

“The formation of DKGX represents a key milestone toward helping cancer patients in Japan. KEW is honored to partner with Denka in this important mission,” said Tuan Ha-Ngoc, Executive Chairman, KEW, Inc.

In the first half of 2017, DKGX will open a commercial clinical comprehensive genomic profiling laboratory in Machida City, Tokyo. Under terms of the agreement, KEW will license its CANCERPLEX® sequencing platform to DKGX. Additional terms of the agreement are not disclosed at this time.

About CANCERPLEX®

CANCERPLEX® is a comprehensive genomic profiling platform for sequencing over 400 cancer-related genes, providing treatment decision support for cancer patients based on a patient’s tumor genomic profile. Using industry-leading sequencing approaches and robust data analytics, a sample acceptance rate of >95% and a rapid turn-around time of 7-10 business days, CANCERPLEX® provides therapeutic options to >90% cancer patients profiled.

About Denka-KEW Genomics

Name         Denka-KEW Genomics
Directory        

Head Office

Nihonbashi Mitsui Tower, 1-1, Nihonbashi-Muromachi

2-chome, Chuo-ku,Tokyo 103-8338, JAPAN

Laboratory

5-1, Asahi-machi 3-chome, Machida-shi, Tokyo 194-8560, JAPAN

Paid-in Capital         10 million JPY
Capital contribution ratio         Denka 55% KEW 45%
Business Launch         April 2017

About KEW, Inc.

KEW, Inc. is a privately-held comprehensive genomic profiling company with headquarters in Cambridge, MA, USA., dedicated to revolutionizing cancer care by providing therapeutic options based on an individual patient’s tumor genomic profile. CANCERPLEX® is KEW’s flagship clinical product family for sequencing and identifying applicable targeted therapies and clinical trials.

About Denka, Co. Ltd.

Denka Co. Ltd., is a public manufacturing and distribution company for a variety of chemical products, including organic and inorganic materials, polymers, electronic materials and pharmaceuticals, contributing to the quality of life and development of society for 100 years through innovations in technology. Focusing on healthcare business sector as a key growth area, Denka is establishing its fifth business division, “Life Innovation”, to accelerate its growth.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170317005524/en/

CONTACT

KEW, Inc.
Jennifer Ring
978-884-3681
jring@kewinc.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • 武田呈报NINLARO™ (ixazomib)用于新诊断多发性骨髓瘤患者及维持治疗的1/2期研究数据
  • Eloxx Pharmaceuticals Receives a US$6 Million Investment from KIP and DCS to Advance a Novel Disease-Modifying Therapy Targeting Genetic Diseases Including Cystic Fibrosis
  • Invacare Corporation Announces Closure of China Manufacturing Facility in Line with Strategic Transformation
  • Takeda and Seattle Genetics Announce Positive Results from Phase 3 ECHELON-1 Clinical Trial Evaluating ADCETRIS® (brentuximab vedotin) in Frontline Advanced Hodgkin Lymphoma
  • Bionext推出Biosight:药品研究的革命性在线平台